|
| PharmacoeconomicsInterest Groups |
|
| Pharmaceutical company |  |
|
|
|
|
Want an early assessment of project opportunity/viability; fearful of exclusion of drugs from formularies and HMOs, recognize need to invest in pharmacoeconomic studies but unsure of their impact on decision makers |
|
|
|
|
| Pharmacists | |
|
|
|
|
Play an important role in deciding which drugs are used in a hospital; this includes formulary decisions and treatment strategy; they help in monitoring patient compliance |
|
|
|
|
| Patients | |
|
|
|
|
Becoming much better informed and organized in pressure groups increasingly prepared to pressure clinicians and lobby governments; Internet will increase coherence of such groups globally resulting in better attention being given to their needs |
|
|
|
|
| Office physicians | |
|
|
|
|
Increasingly cost-conscious; generally concerned with long term patient outcome; efficacy focused, they are keen to see time saving benefits (reduced return visits) |
|
|
|
|
|
|
|
|
|
Managed case organizations/health insurance companies |
|
|
|
| |
|
|
|
|
Want substantive real-world outcome data to select most cost effective drugs; may not have infrastructure to provide this data; not easily impressed with small scale PE studies |
|
|
|
|
| Reimbursement agency | |
|
|
|
|
Responsible for setting a reimbursement level/copayment for the drug; concerned with the impact of new medicine on health care expenditures; will set pricing which reflects the perceived cost effectiveness of the new medicine |
|
|
|
|